Welcome to our dedicated page for CYTOKINETICS SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
CYTOKINETICS INC (CYTK) executive Fady Ibraham Malik, EVP Research & Development, reported an option exercise-and-sell transaction. On 2026-08-18 he exercised 3,500 non-qualified stock options at an exercise price of $7.80 per share, acquiring 3,500 shares of common stock, and on the same date sold 3,500 common shares at $75.82 per share. Following the option exercise, he held 30,386 options of this grant directly. The transactions were affirmed as made pursuant to a Rule 10b5-1 trading plan.
Cytokinetics, Incorporated received an updated ownership report from Wellington Management Group LLP and related entities, filing Amendment No. 2 to a Schedule 13G for its Common Stock (CUSIP 23282W605) as of 06/30/2026.
Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively report 7,116,724 shares of Cytokinetics common stock as beneficially owned, representing 5.12% of the class. These entities report 0 shares with sole voting or dispositive power, 6,231,890 shares with shared voting power, and 7,116,724 shares with shared dispositive power. The shares are owned of record by clients of various Wellington investment advisers, and no single client is reported to hold more than five percent of the class.
CYTOKINETICS INC President & CEO Robert I. Blum exercised options for 7,500 shares of common stock at an exercise price of $10.60 per share and on the same date sold 7,500 shares at $76.76 per share, under a Rule 10b5-1 trading plan. Following the option exercise, he held 171,745 options directly, plus 2,083 shares of common stock in each of two irrevocable trusts reported as indirect ownership.
Cytokinetics reported Q2 2026 results highlighted by initial MYQORZO sales and a major equity raise. Total revenues were $28.6 million, driven by $25.3 million in MYQORZO net product revenue and $3.3 million in collaboration revenue, with no license or milestone revenues. Net loss widened to $198.8 million, or $1.50 per share, as selling, general and administrative costs increased with the commercial launch.
The company ended June 30, 2026 with approximately $1.7 billion in cash, cash equivalents and investments, compared to $1.1 billion at March 31, 2026, supported by a public offering of 11,338,028 shares at $71.00 per share that generated about $760.1 million in net proceeds. As of quarter end, over 700 healthcare providers had prescribed MYQORZO, approximately 1,500 patients had been dispensed therapy and over 80% of patients on therapy were on paid prescriptions. Cytokinetics announced positive Phase 3 ACACIA-HCM results in non-obstructive hypertrophic cardiomyopathy and plans to file a supplemental NDA in the fourth quarter of 2026, while raising its 2026 GAAP combined R&D and SG&A expense guidance to $860–$890 million.
CYTOKINETICS INC EVP and Chief Commercial Officer Andrew Callos exercised 14,000 non-qualified stock options for Common Stock at $23.26 per share and, on the same date, sold 14,000 shares at $79.88 per share under a Rule 10b5-1 trading plan. Following the exercise, he reports 10,000 stock options remaining. The option grant vests over four years, with 25% after one year and the balance vesting monthly over 36 months, subject to continued employment.
Cytokinetics, Incorporated insider Andrew Callos filed to sell common stock. The notice lists a planned sale of 24,000 shares of common stock on July 30, 2026, to be effected through Morgan Stanley Smith Barney LLC in connection with an exercise of stock options.
The filing also details prior Rule 10b5-1 plan sales of common stock over the past three months, including transactions on May 1, 2026, May 5, 2026, June 1, 2026, and June 30, 2026, with share counts and aggregate proceeds disclosed for each sale.
Robert I. Blum, President & CEO of Cytokinetics, exercised 7,500 stock options at $10.60 per share into common stock on July 27, 2026 and sold 7,500 shares at $80.87 per share, pursuant to a Rule 10b5-1 trading plan. Following the option exercise, 179,245 options of this type remain directly held. The filing also reports indirect holdings of 2,083 shares in each of The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust.
CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik exercised 3,500 non-qualified stock options at $7.80 per share on July 21, 2026, receiving 3,500 common shares and selling the same number at $80.59 per share. The transactions, conducted under a Rule 10b5-1 trading plan, left him holding 33,886 non-qualified stock options.